Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 751 - 800 out of 12,743

Document Document Title
WO/2015/139602A1
Disclosed are 2'-substituted-2,2'-dehydrated uridine or 2'-substituted-2,2'-dehydrated cytidine compounds as represented by the following general formula I and preparation method thereof. The present invention also relates to a method of...  
WO/2015/137121A1
Provided is a means for producing a non-natural nucleoside analog in which position 5 is a hydroxyl group and which is for synthesizing a triazole linking-type non-natural nucleotide having a structure bonded via organic groups containin...  
WO/2015/133491A1
Provided are: an oligonucleotide having, at 5'-terminal thereof, a nucleotide or nucleoside residue represented by formula (I) {wherein X1 represents an oxygen atom or the like; R1 represents formula (IIA) (wherein R5A represents a halog...  
WO/2015/133411A1
The purpose of the present invention is to search for: a free acid crystal of 3',5'-cyclic diguanylic acid, which does not contain a salt with a metal such as cobalt and magnesium; and a method for producing the crystal in a simple manne...  
WO/2015/134780A1
Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be admi...  
WO/2015/134334A1
Gemcitabine analogs, including monophosphorylated analogs, are described herein and are suitable for use in pharmaceutical compositions, kits and treatment methods. The treatment methods include treatment of viral infections, including, ...  
WO/2015/132577A1
The invention relates to compounds for use in the modification of compounds comprising nucleic acid sequences (such as oligonucleotides or the like), to modified oligonucleotides, to the delivery of modified oligonucleotides to cells and...  
WO/2015/125845A1
 Provided are: a oligonucleotide having at least one bond represented by formula (I): (in the formula, Q is S or O, X1 does not exist, or is a substituted or unsubstituted alkylene in which O may be interposed, X2 is a substituted or u...  
WO/2015/125783A1
Disclosed are a crosslinked nucleoside and nucleotide. The nucleoside has a 2',4'-crosslinked structure, and is represented by formula (I). An oligonucleotide containing a 2',4'-crosslinked artificial nucleotide according to the present ...  
WO/2015/126995A1
The present disclosure encompasses solid state forms of Sofosbuvir and pharmaceutical compositions thereof.  
WO/2015/120237A2
The application discloses nucleoside derivatives of Formula I as inhibitors of Influenza RNA replication. In particular, the application discloses the use of purine and pyrimidine nucleoside derivatives of Formula I as inhibitors of Infl...  
WO/2015/120065A1
A method of reducing a subject's plasma triglyceride level, comprising administering to a subject in need thereof a gamma-secretase inhibitor in an amount effective to reduce the subject' s plasma triglyceride level.  
WO/2015/051173A3
The present disclosure provides alternative nucleosides, nucleotides, and polynucleotides, and methods of use thereof.  
WO/2015/112014A1
The present invention relates to a process comprising the step of reacting a (hetero)aryl 1,3-dipole compound with a (hetero)cycloalkyne, wherein: a (hetero)aryl 1,3-dipole compound is defined as a compound comprising a 1,3-dipole functi...  
WO/2015/112013A1
The present invention relates to a process for attaching an N-acetylgalactosamine- (hetero)arylmoiety to an N-acetylglucosaminemoiety, the process comprising the step of contacting the N-acetylgalactosamine-(hetero)arylmoiety with the N-...  
WO/2015/112016A1
The present invention relates to a cycloaddition process comprising the step of reacting a halogenated aliphatic 1,3-dipole compound with a (hetero)cycloalkyne according to Formula (1): Preferably, the (hetero)cycloalkyne according to Fo...  
WO/2015/025283A3
The present invention is directed to novel carbonic anhydrase IX inhibitors comprising a nitroimidazole moiety substituted with a heterocycle or phosphinate and having sulfonamide, sulfamate or sulfamide groups. The present invention is ...  
WO/2015/064718A8
Provided is a means for preventing the inactivation of a photoresponsive nucleic acid probe by suppressing the formation of a photocrosslink between a photoresponsive base having a photocrosslinkable vinyl structure and a photocrosslinka...  
WO/2015/101183A1
The invention relates to uracil nucleotide analogs, preparation methods therefor and uses thereof. Specifically, the invention provides uracil nucleotide analogic compounds having the following formula (I), stereoisomers or pharmaceutica...  
WO/2015/097605A1
The present disclosure relates to processes for the preparation of sofosbuvir or of its pharmaceutically acceptable salts. The present disclosure also provides intermediates useful in the synthesis of sofosbuvir.  
WO/2015/099989A1
Crystalline solid forms of the anti-HCV compound (S)-isopropyl 2-((S)-(((2R,3R,4R,5R)- 5-(2,4-dioxo-3,4-dihydropyrimidin-l(2H)-yl)-4-fluoro-3-hydro xy-4- methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino) propanoate (Compound I...  
WO/2015/095419A1
Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be admi...  
WO/2015/095305A1
Provided herein are methods for the production of cyclic phosphate, cyclic phosphoramidate, cyclic thiophosphate, and cyclic phosphonate nucleoside compounds. Also provided herein are compounds useful in the production of cyclic phosphat...  
WO/2015/085497A1
The present invention provides novel processes for the preparation of regadenoson having the formula (I). In some embodiments, the intermediates for the synthesis of regadenoson are also provided.  
WO/2014/178082A4
The present invention provides novel chiral serinyl functionalized tethered oligonucleotides i.e. R/S serinyl functionalized tethered oligonucleotides and the process of preparation thereof. Specifically, the present invention provides a...  
WO/2015/081867A1
The present invention provides a gemcitabine derivative of formula (I) and a method for preparing the same. The present invention further relates to a pharmaceutical composition comprising a pharmaceutically effective dose of the gemcita...  
WO/2015/081297A1
Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be admi...  
WO/2015/081133A2
Provided herein are compounds, compositions and methods for the treatment of liver cancer such as hepatocellular carcinoma, cholangiocarcinoma, or biliary tract cancer. In certain embodiments, compounds and compositions of nucleoside der...  
WO/2015/077966A1
Provided are crystalline forms of the compound of formula (I), which is a nucleoside inhibitor of HCV, processes for the preparation thereof, and pharmaceutical compositions comprising these crystalline forms.  
WO/2015/077292A1
Described herein are 5-position modified cytosine nucleotides and nucleosides as well as phosphoramidites and triphosphates derivatives thereof. Further provided are methods of making and using the same, and compositions and uses of the ...  
WO/2015/077368A1
The present invention regards nucleoside 5'-monophosphate compounds of Formula I, their preparation and their uses. In some embodiments, such compounds are useful to treat hepatitis C viral infections.  
WO/2014/078295A8
The present invention provides compounds according to formula I and pharmaceutically acceptable salts thereof. For compounds of formula I, R1 and R2 are independently selected from the group consisting of H, -C(=O) (CH2)2-aryl, and C(=O)...  
WO/2015/073706A1
The present invention relates to DOT1L inhibitors. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating disorders in which DOT1-mediated protein methylation plays a part, su...  
WO/2015/065661A1
Methods for removing 1,3,5-trimethylhexahydro-1,3,5-triazine and N-methylenemethanamine from a N-methylimidazole and methods for making oligonucleotides using N-methylimidazole are provided. In one embodiment, a method for removing 1,3,5...  
WO/2015/066370A1
Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be admi...  
WO/2015/066382A1
Compositions containing nicotinamide riboside (NR) are provided. NR containing compositions are used in the care or treatment of skin and skin conditions. In some embodiments, the invention relates to pharmaceutical compositions and cosm...  
WO/2015/066162A1
The present invention relates to methods and intermediates for synthesizing 2'-deoxy-2',2'-difluorotetrahydrouridine compounds.  
WO/2015/065956A1
The present invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof.  
WO/2015/064718A1
 Provided is a means for preventing inactivation of a photoresponsive nucleic acid probe by suppressing formation of photocrosslinking between a photoresponsive base having a photocrosslinkable vinyl structure and a photocrosslinkable ...  
WO/2015/066001A1
Methods and compositions are provided for identifying novel ligands for a protein target.  
WO/2015/026845A3
Provided herein is technology relating to the manipulation and detection of nucleic acids, including but not limited to compositions, methods, and kits related to nucleotides comprising a chemically reactive linking moiety.  
WO/2015/064223A1
This nucleotide derivative or a salt thereof is represented by one of formulae (I-1) to (I-6). (In formulae (I-1) to (I-6), R1-R5, A1-A3, B, X, Y and k represent the meanings set forth in claim 1.)  
WO/2015/061507A1
This invention is related to nucleic acid chemistry and describes novel 1,2- dithiolane functionalized nucleoside phosphoramidites (1, Chart 1) and corresponding solid supports (2, Chart 1). In addition to these derivatives, 1,2- dithiol...  
WO/2015/061683A1
Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be admi...  
WO/2015/056213A1
The invention provides compounds of the formula (I) wherein B is a nucleobase selected from the groups (a) to (d): and the other variables are as defined in the claims, which are of use in the treatment or prophylaxis of hepatitis C viru...  
WO/2014/052896A9
This disclosure relates to the use of uridine diphosphate (UDP) derivatives, salts and/or prodrugs thereof for the treatment of inflammatory conditions (e.g., psoriasis) and glaucoma, to prodrugs of UDP derivatives, compositions comprisi...  
WO/2015/054465A1
Disclosed herein are nucleosides, nucleotides and nucleotide analogs, methods of synthesizing the same and methods of treating diseases and/or conditions such as a Picornavirus and/or Flaviviridae infection with one or more nucleosides, ...  
WO/2015/050467A1
The subject matter of the invention is novel 2',3'-dideoxy-5-fluorouridine derivatives of general formula 1. wherein: R1 denotes cinchona alkaloid fragment with defined absolute configuration at C-8 and C-9 atoms. In the second aspect, t...  
WO/2015/051169A2
The present disclosure provides alternative sugar moieties and polynucleotides comprising such sugar moieties, and methods of use thereof.  
WO/2015/050468A1
The subject matter of the invention is novel 2,3'-anhydro-2'-deoxy-5-fluorouridine derivatives of general formula (1) where R is a trifluoromethyl, 2,2,2-trifluoroethyl, difluoromethyl, perfluoroethyl, 1-fluoroethyl, 2-fluoroethyl, 1,1-d...  

Matches 751 - 800 out of 12,743